Pulmatrix reports positive Phase 1 results for inhaled migraine drug PUR3100; Tmax 5 min, fewer GI side effects

Pulmatrix, Inc.

PUR3100 was safe and well-tolerated; no emesis in any dose group; lower nausea incidence vs IV DHE.
Peak plasma concentration (Cmax) reached targeted therapeutic range at all three doses; Tmax of 5 minutes.
Phase 2 dose selection underway; FDA meeting requested in January 2023.
Study enrolled 26 healthy subjects in double-dummy, double-blinded design comparing inhaled PUR3100 vs IV DHE.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.